Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled phase 2 trial of pleconaril added to acetylcholinesterase inhibitor/memantine therapy in Alzheimer's disease
2017-004125-32Phase 2Completed
- Sponsor
- Apodemus AB
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Pleconaril add-on with Placebo add-on (2 arms). Primary endpoint: Change in ADAS-cog total score from baseline to 12 months. Started Dec 2017; status: completed.
02
Drugs
pleconaril
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-004125-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004125-32.